## VTRS: Viatris Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.7% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($10.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited**
- Source: PR Newswire | 20251206T140216 | Bullish | Relevance: 99%
-  Viatris has announced a definitive agreement to sell its entire equity stake in Biocon Biologics Limited to its partner Biocon Limited for $815 million, comprising $400 million in cash and $415 million in Biocon equity shares. This transaction will accelerate the expiration of biosimilars non-compete restrictions, allowing Viatris to re-enter the biosimilars market globally, with immediate expiration for ex-U.S. markets and November 2026 for U.S. markets. The agreement is expected to close in Q1 2026, marking a strategic step in Viatris's evolution to build a diverse pharmaceutical portfolio.

**2. Viatris shareholders elect directors and approve proposals at annual meeting By Investing.com**
- Source: Investing.com Australia | 20251206T012308 | Neutral | Relevance: 98%
- Viatris Inc. shareholders approved key proposals at their 2025 annual meeting, including the election of thirteen director nominees and advisory approval of executive compensation. They also ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2025. The company's stock symbol is VTRS on the NASDAQ Stock Market.

**3. Viatris shareholders elect directors and approve proposals at annual meeting By Investing.com**
- Source: Investing.com Nigeria | 20251206T010931 | Neutral | Relevance: 98%
-  Viatris Inc. shareholders approved key proposals at their 2025 annual meeting, including the election of thirteen director nominees, advisory approval of executive compensation, and ratification of Deloitte & Touche LLP as independent auditor. The results, based on an SEC filing, showed strong majority support for all resolutions. This follows a positive Q3 2025 earnings report where Viatris surpassed analyst expectations for EPS and revenue, though the stock experienced a decline due to other market factors.

**4. VTRS LAWSUIT ALERT: Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming Deadline**
- Source: KSN.com | 20251206T080859 | Neutral | Relevance: 98%
-  Levi & Korsinsky LLP has announced a class action lawsuit against Viatris Inc. (NASDAQ:VTRS) for alleged securities fraud, seeking to recover losses for investors who bought shares between August 8, 2024, and February 26, 2025. The lawsuit claims Viatris misrepresented the impact of a failed FDA inspection of its Indore, India facility, causing a significant stock price drop after disappointing 2025 guidance was released. Investors affected are encouraged to learn about their rights to potential recovery.

**5. Viatris Inc. Stock Rises Friday, Outperforms Market**
- Source: 富途牛牛 | 20251208T160855 | Bullish | Relevance: 98%
- Viatris Inc. (VTRS) saw its stock rise on Friday, outperforming the market with a 2.10% increase. This news was published alongside Unity Software's Q4 earnings, which reported a 35% revenue increase year-over-year to $609 million, exceeding analyst estimates.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-3.3%)
- Price (T.Rowe) Assoc: 7.3% (+6.7%)
- Blackrock Inc.: 7.1% (-1.1%)
- Davis Selected Advis: 6.0% (+4.5%)
- State Street Corpora: 4.8% (+0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +2.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 4.5x attractive for 7% earnings growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.8B |
| Beta | 0.83 |
| 52W Range | $6.85 - $13.13 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 4.5 |
| Current P/E | 4.8 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.5% to 1.7% (+2.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.3pp (needs >4.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. AM_20 at 3.8% shows strong absolute momentum above own 20MA. Outperforming sector by 5.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.74% (CS: 69) | Neutral |
| RSI_14 | 63.6 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 1.037x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.171x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $11.09
- **Stop Loss:** $10.55 (4.9% risk)
- **Target:** $11.63 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 925
- **Position Value:** $10,258.25
- **Portfolio %:** 10.26%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-26 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.62 | $0.67 | +8.5% |
| 2025Q2 | $0.56 | $0.62 | +11.6% |
| 2025Q1 | $0.49 | $0.50 | +1.6% |
| 2024Q4 | $0.57 | $0.54 | -5.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*